Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis

Clinical trial NCT01510860 · COMPLETED

Trial details

NCT number: NCT01510860
Sponsor: Dr. Falk Pharma GmbH
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Primary Biliary Cirrhosis

Start date: 2008-11-01
Primary completion: 2010-07-01
Enrollment: 65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.